Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest

Publication date: Available online 6 June 2017
Source:Clinical Biochemistry
Author(s): Oscar J. Cordero, Rubén Varela-Calviño, Tania López-González, Milica Grujic, Zorica Juranic, Coral Mouriño, Íñigo Hernández-Rodríguez, Marina Rodríguez-López, Bruno Aspe de la Iglesia, José María Pego-Reigosa
ObjectivesRheumatoid arthritis (RA) patients show low serum levels of the Ag dipeptidyl peptidase IV (DPP-IV/CD26), both soluble CD26 (sCD26) concentration and its DPP-IV activity. The aim of this study was to test if anti-DPP-IV/CD26 Abs (Anti-CD26) cleared sCD26.Design & methodsSerum Anti-CD26 and Total titers (as comparison) of isotypes IgA, IgM and IgG as well as sCD26 concentration and DPP-IV activity were measured in a cohort of RA patients undergoing different biological and non-biological therapies (n=105) and controls (n=50).ResultsAnti-CD26 levels were increased approximately two-fold for each isotype in RA, were not related to the sCD26 clearance, showed several correlations with disease activity parameters, were significantly higher in smokers and they were not ACPA. Anti-CD26 Igs showed high diagnostic power (82% sensitivity and 96% specificity) and their levels differed amongst the different groups of patients stratified by the type of therapy.ConclusionsAs DPP-IV/CD26 is an associated to factors triggering RA in the lung and periodontal tissue, these results suggest that Anti-CD26 isotypes may participate in pathogenesis and may be useful as biomarkers for earlier diagnosis and/or precision medicine.



from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r4AwDm
via IFTTT